<DOC>
	<DOC>NCT00941343</DOC>
	<brief_summary>Primary Objective: - To assess the sexual function of Benign Prostatic Hyperplasia patients Secondary Objective: - To evaluate the association between Lower Urinary Tract Symptoms severity and sexual disorders - To compare the sexual function, urinary symptoms and Quality of Life of Benign Prostatic Hyperplasia patients on XATRAL 10mg OD among the different regions - To correlate the Male Sexual Health Questionnaire(MSHQ) and 5-item version of the International Index of Erectile Function (IIEF-5) - To assess the onset of action of XATRAL 10mg OD - To assess the peak urinary flow rate - To assess the safety and the tolerability of XATRAL 10mg OD</brief_summary>
	<brief_title>Benign Prostatic Hyperplasia in Taiwan</brief_title>
	<detailed_description />
	<mesh_term>Hyperplasia</mesh_term>
	<mesh_term>Prostatic Hyperplasia</mesh_term>
	<mesh_term>Prostatic Diseases</mesh_term>
	<mesh_term>Alfuzosin</mesh_term>
	<criteria>Inclusion criteria Male suffering from moderate to severe lower urinary tract symptoms (LUTS), suggestive of symptomatic Benign Prostatic Hyperplasia (BPH) Sexually active Sexual attempts at least once per month Exclusion criteria Known history of hepatic or severe renal insufficiency unstable angina pectoris concomitant threateninglife condition Previous transurethral resection of the prostate (TURP) Had a minimally invasive procedure within 6 months prior to inclusion Planned prostate surgery or minimally invasive procedure during the whole study period Active urinary tract infection or acute prostatitis Neuropathic bladder Diagnosed prostate cancer Patients having received 5reductase inhibitors or Lower Urinary Tract Symptoms (LUTS) related phytotherapy or antimuscarinics drug for OAB or 1blockers within 1 month prior to inclusion Patients receiving any treatment for erectile dysfunction within 1 month prior to inclusion History of postural hypotension or syncope Known hypersensitivity to alfuzosin Patients illiterate or unable to understand or to complete the questionnaires Patients having participated in any clinical study in the past month Prostate Specific Antigen (PSA)&gt; age specific Prostate Specific Antigen value, without using prostate biopsy to rule out prostate cancer The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.</criteria>
	<gender>Male</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2010</verification_date>
</DOC>